AstraZeneca Donates $27.6 Million Worth Of Iressa To China
This article was originally published in PharmAsia News
AstraZeneca is donating $27.6 million worth of its Iressa (gefitinib) cancer drug to a Chinese foundation to distribute to needy cancer patients. The China Charity Federation already has distributed $10 million worth of the tablets to patients with advanced non-small cell lung cancer and plans to distribute the rest this year. A vice president of the Anglo-Swedish AstraZeneca announced the gift at a ceremony in Beijing. The drug is available to those who have had at least one chemotherapy treatment and have used Iressa for at least six months before applying for the free tablets. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.